November 16, 2021 6:15pm

A sector slight comeback at the mid-day collapses at session’s end

Pre-open indication results: 3 HITs, 1 MISS and 1 PUMPED

The Biostage (BSTG) Chronicles: pumping the share price with NO clinical trial from a one (1) year old IND and a negligence rejection of reimbursement in a terminal death suit

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing. Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist and pundit; it is that your life and your bank account are largely tied to your questioning

 

The Dow closed UP +54.77 points (+0.15%); the S&P closed UP +18.10 points (+0.39%) while the Nasdaq closed UP +120.01 points (+0.76%)

 

Henry’omics:

Stem, cell and gene therapy sector equities jumped after Monday’s losing session after coming off a losing week … and the decline continues!

While indexes gained on Tuesday after a strong October retail sales report.

The markets were coming off a day of shifting trading Monday that ultimately ended slightly lower for indexes as investors continued digesting economic data from the previous week that swelled concerns about heightening inflation.

 

Economic data Docket: The latest retail sales figures for October showed consumers were increasing their spending, with sales jumping 1.7%. That compares to a 0.8% increase in the prior month. The report showed broad strength in a number of categories from autos to sporting goods. Online sales were up 10.2% from a year ago. The gains came even as consumer prices surged 6.2% year-over-year last month, inflation not seen since the 1990s. <CNBC>

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Tuesday opened negative at 10/24 and 1 acquired, flipped positive at the mid-day at 18/16, and 1 acquired, ending with a negative close of 16/18 and 1 acquired;
  • Monday opened negative at 13/19, 2 flats and 1 acquired, stayed negative at the mid-day at 12/20, 2 flats, 2 flats and 1 acquired, ending with a negative close of 13/20, 2 flats and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “the sector’s eight (8) session stumble. Time to go fishing, use a high/low rig to bottom fish a mixed-equities catch, that will bounce in your portfolio.” …  https://www.regmedinvestors.com/articles/12185

 

Pre-open indication results: 3 HITs: < Intellia Therapeutics (NTLA +$3.97); SELL: Pluristem (PSTI -$0.14); BUY: Regenxbio (RGNX +$0.12)> 1 MISS: SELL:  Sage Therapeutics (SAGE +$0.33> and 1 PUMPED: Biostage (BSTG +$0.39)>  

 

The Biostage (BSTG) Chronicles: Tuesday closed up +$0.39 with 2,687 shares traded after Monday closed flat with 35 shares traded after Friday with 0 shares traded. Where is the SEC and Nasdaq monitoring?

 

Key Metric - volume

Sector volume LOW with 3 of the 16-upside having higher than the 3-month average volume with LOW volume of 5 of 18-downside having higher than the 3-month average volume;

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 16):

  • Intellia Therapeutics (NTLA +$3.97),
  • BioLife Solutions (BLFS +$2.95 after Monday’s +$2.59),
  • Fate Therapeutics (FATE +$1.76 after Monday’s -$2.12),
  • CRISPR Therapeutics (CRSP +$1.50 after Monday’s -$3.85),
  • Editas Medicine (EDIT +$1.19 after Monday’s -$1.91), 
  • Biostage (BSTG +$0.39 after Monday’s $0.00),
  • Sage Therapeutics (SAGE +$0.33 after Monday’s -$1.18),
  • MiMedx (MDXG +$0.25 after Monday’s -$0.47),
  • Homology Medicine (FIXX +$0.23),
  • Chinook Therapeutics (KDNY +$0.17),

Hammered in today’s market (10 of 18):

  • ReNeuron (RENE.L -$3.00 after Monday’s -$2.50),
  • Ultragenyx (RARE -$1.44 after Monday’s +$0.01),
  • Mesoblast (MESO -$0.67 after Monday’s +$0.82),
  • Alnylam Pharmaceuticals (ALNY -$0.37 after Monday’s +$2.44),
  • Vericel (VCEL -$0.33),
  • Global Blood Therapeutics (GBT -$0.30 after Monday’s +$1.16),
  • Cellectis SA (CLLS -$0.22 after Monday’s -$0.48),
  • Pluristem (PSTI -$0.14 after Monday’s +$0.12),
  • Voyager Therapeutics (VYGR -$0.13 after Monday’s +$0.04),
  • Ionis Pharmaceuticals (IONS -$0.12 after Monday’s +$0.10),

Closing Flat:

  • 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +0.57% and XBI closed up +0.50%
  • Monday, the IBB closed down -0.53% and XBI closed down -2.09%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.12 points or -0.73% at 16.37
  • Monday was up +0.20 points or +1.23% at 16.49

 

November, the second month of Q4/21:

Tuesday closed negative with 16 incliners, 18 decliners and 1 acquired

Monday (11/15) closed negative with 13 incliners,20 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE:  After a week of whipsaw, another negative action follows after four (4) new net losses within a sector close …

With the stock market rally getting close to extended again, investors may want to be cautious about substantially adding exposure, especially in sector names.

It's not surprising that after what has been a bad run of negative closes – nine (9) is an unusual run for the sector undergoing an earnings proctology examination.

  • Q3 earnings reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.